Peptide vaccines are an attractive strategy to engineer the induction of highly targeted immune responses and avoid potentially allergenic and/or reactogenic protein regions. However, peptides by themselves are often unstable and poorly immunogenic, necessitating the need for an adjuvant and a specialised delivery system. We have developed a novel peptide delivery platform (PilVax) that allows the presentation of a stabilised and highly amplified peptide as part of the group A streptococcus serotype M1 pilus structure (PilM1) on the surface of the non-pathogenic bacterium Lactococcus lactis. To show proof of concept, we have successfully inserted the model peptide Ova 324-339 into 3 different loop regions of the backbone protein Spy0128, which resulted in the assembly of the pilus containing large numbers of peptide on the surface of L. lactis. Intranasal immunisation of mice with L. lactis PilM1-Ova generated measurable Ova-specific systemic and mucosal responses (IgA and IgG). Furthermore, we show that multiple peptides can be inserted into the PilVax platform and that peptides can also be incorporated into structurally similar, but antigenically different pilus structures. PilVax may be useful as a cost-effective platform for the development of peptide vaccines against a variety of important human pathogens.
The crystal structure of the FCT-2 type pilus backbone protein (Spy0128) revealed an immunoglobulin-like fold with intramolecular isopeptide bonds resulting in a protease-resistant and very stable protein conformation 15 . Linkage between Spy0128 monomers is achieved by a transpeptidase (sortase C, Spy0129) reaction between the carboxyl group of a C-terminal threonine and the ε-amino group of an internal lysine, leaving the N-terminus protruding along the pilus fibre 15 . The pili are distributed over the entire GAS cell surface 17 .
Mucosal routes for vaccine delivery have gained increased interest in modern vaccinology. More recently, non-pathogenic food grade bacteria, such as L. lactis were shown to work as safe and efficacious live antigen carriers that elicit specific and protective immune responses against the target protein [18] [19] [20] [21] [22] . L. lactis secreting human IL-10 has also been used in a phase I clinical trial to treat patients with Crohn's disease 23 .
It was shown previously that complete S. pyogenes pilus structures can be expressed on the surface of L. lactis [24] [25] [26] [27] [28] . Furthermore, it was reported that a model protein, maltose-binding protein (MBP), fused to the tip pilin of a GAS serotype M3 strain was able to induce mucosal MBP-specific antibody responses, showing proof-of-concept for a potential vaccine strategy 27 .
The aim of our study was to demonstrate that L. lactis bacteria expressing a complete GAS pilus structure can be used as a platform to carry stabilised peptide antigens for the generation of mucosal vaccines against selected human pathogens. We show that the model peptide Ova 324-339 , a well characterised B cell epitope 29, 30 inserted at suitable regions of the protease-resistant backbone pilus protein can be stably expressed in large numbers as part of the multimeric GAS pilus structure on the surface of L. lactis ( Supplementary Figure 1) and triggers peptide-specific mucosal immune responses after intranasal immunisation of mice.
Results
Insertion of a model peptide into selected regions within Spy0128. The GAS serotype M1 pilus (PilM1) encoded in the FCT-2 region has been extensively characterised 13, 14, 16, 17 and the crystal structure of the pilus backbone protein Spy0128 has been solved 15 . In order to identify potential integration sites for peptide epitopes, the protein structure of Spy0128 was analysed for surface accessible non-structured loop regions ( Fig. 1 ). Based on this analysis, we selected 6 different loop regions for peptide integration. These include the βB-βC loop, the βD-βE loop and the βE-βF loop in the N-terminal domain and the β2-β3 loop, the β3-β4 loop and the β9-β10 loop in the C-terminal domain (Fig. 1 ). Furthermore, the free Spy0128 N-terminus and the region between the two Spy0128 domains (βG-β1 interdomain region) were also selected ( Fig. 1 ). As the interdomain region is not well exposed we also inserted a peptide linker at this position.
As Spy0128 is expressed as a precursor with a N-terminal signal peptidase domain and a predicted cleavage site between Gly23 and Glu24, the N-terminus peptide integration site was introduced between Asn28 and Gly29. Table 1 shows the amino acid sequences of all the targeted regions before and after the introduction of the model peptide. The complete pilus structure was expressed in the food-grade bacterium L. lactis under the control of the constitutive P23 lactococcal promotor. To evaluate the successful assembly of the modified pili, L. lactis cell wall extracts were analysed in Western blots using specific anti-M1_Spy0128 antibodies (Fig. 2) . Correctly assembled pili appear as a high molecular weight (HMW) laddering pattern due to the covalent linkage of variable numbers of individual pilin monomers, as seen for L. lactis expressing the unmodified M1 pilus ( Fig. 2A) . Unfortunately, insertion of the Ova 324-339 peptide into the N-terminal region or the βG-β1interdomain region of Spy0128 did not result in expression of a pilus structure (Supplementary Figure 2 ). The addition of a GSGSG linker region on both ends of the Ova 324-339 peptide in the βG-β1interdomain region also failed to produce pili (data not shown). Introduction of the Ova 324-339 peptide into the βB-βC, the βD-βE, and the β2-β3 loops also affected pilus assembly ( Fig. 2A ). Western-blot analysis of the individual cell fractions revealed that L. lactis with Ova-peptide engineered into the βC-βD, β2-β3 loops or the interdomain region (βG-β1) expressed monomeric Spy0128 protein in the protoplast fraction with a slightly higher molecular weight than rSpy0128. In contrast, L. lactis with Ova-peptide at the βD-βE or the N-terminal region did not show Spy0128 protein in any cell fraction (Supplementary Figure  2 ). However, insertion of the Ova 324-339 peptide into the βE-βF, the β3-β4 or β9-β10 loop regions resulted in assembled pili, indicated by a high-molecular weight banding pattern on Western blots with anti-M1_Spy0128 antibodies ( Fig. 2A ). Flow cytometry was used to investigate whether or not peptide integration in the βE-βF loop, the β3-β4 loop or the β9-β10 loop had an effect on the amount of Spy0128 pilus proteins expressed on 
Intranasal immunisation generates mucosal and systemic antibody responses in mice.
After successful integration of the Ova 324-339 peptide into the Spy0128 pilus backbone protein and confirmed assembly of the modified pilus structure on the surface of the food-grade bacterium L. lactis, we were able to test our hypothesis that this peptide delivery platform could be used as a strategy to generate mucosal immune responses. To investigate if L. lactis PilM1-Ova preferentially targets specific IgG subclasses, we tested IgG1 and IgG2a responses in serum from vaccinated mice ( Fig. 3C ). There was no significant difference between IgG1 and IgG2a responses when mice were vaccinated with L. lactis PilM1-Ova. However, mice vaccinated with synthetic Ova 324-339 plus CT-B generated significantly more IgG1 than IgG2a (p < 0.05).
As intranasal immunisation is expected to also generate mucosal responses, IgA titres were measured in serum ( Fig. 4A and B ), BAL fluid ( Fig. 4C ) and saliva ( Fig. 4D ). As seen for IgG, consistent IgA responses in serum of L. lactis PilM1, L. lactis PilM1 + Ova and L. lactis PilM1-Ova groups were detected against Spy0128, with titres of approximately 10 3 to 5 × 10 4 (Fig. 4A ). Importantly, significant Ova-specific serum IgA responses were found in most mice immunised with L. lactis PilM1-Ova (titres ≥ 10 3 , p < 0.0005). In contrast, mice immunised with L. lactis PilM1, L. lactis PilM1 + Ova or synthetic Ova 324-339 peptide (even when mixed with CT-B) all failed to generate detectable Ova-specific serum IgA (Fig. 4B ). Similar responses were also seen in BAL fluid and saliva samples, although IgA titres were generally lower ( Fig. 4C and D). The only difference was that Ova 324-339 peptide plus CT-B induced Ova-specific IgA responses in BAL fluid, at a similar level to mice immunised with L. lactis PilM1-Ova.
Expression of multiple peptides in the PilM1 pilus. Our cloning strategy (peptides with flanking XhoI
and SalI sites into the XhoI site of the spy0128 gene) allows the insertion of multiple peptides in succession. XhoI and SalI digestions generate compatible restriction site overhangs, which result in a hybrid site after ligation that is not recognised by either XhoI or SalI. Therefore, cloning of the first peptide into the pilin gene neutralises one XhoI site and leaves the remaining XhoI site for cloning of a second peptide in frame with the first peptide. Using this strategy, we have inserted a second model peptide (J14, derived from the S. pyogenes M protein 31 ), downstream of the Ova 324-339 peptide in the βE-βF loop (Table 1a ). This peptide fusion consists of a total of 47 amino acids and was successfully expressed within the PilM1 pilus on the surface of L. lactis as shown by the formation of high-molecular weight bands on Western blots (Fig. 5A ). However, flow cytometry revealed that the expression 
Expression of peptides in the backbone pilins of other S. pyogenes pilus types. Several antigen-
ically different pilus types have been found in S. pyogenes 17 . The FCT-3 and FCT-4 pili each possess a backbone pilin with a predicted two-domain structure similar to the FCT-2 backbone pilin (Spy0128), despite rather low amino acid identities (38% and 40%, respectively). We used the SWISS PDB modeller to generate protein structure models of both the FCT-3 type (from S. pyogenes serotype M18) and the FCT-4 type (from S. pyogenes serotype M28) backbone pilins (Fig. 6A ). This enabled us to identify the loop regions equivalent to the βE-βF, β3-β4 and β9-β10 loops in the M1_Spy0128. Insertion of the Ova 324-339 peptide into the βE-βF loop region of M18_Spy0128 (Table 1b ) resulted in expression and assembly of the M18 pilus (PilM18) on the surface of L. lactis (Fig. 6B ). Similar to Spy0128 βE-βF-Ova, the insertion of the Ova 324-339 peptide into the βE-βF loop region of M18_Spy0128 resulted in decreased expression of the backbone pilin (Fig. 6C ).
Discussion
Mucosal routes for vaccine delivery have gained an increased interest in modern vaccinology. Mucosal surfaces represent a major entry site of many pathogens. Hence, the ability of a vaccine to induce a local mucosal immune response is an efficient prophylactic strategy. Mucosal vaccination also has an advantage over parenterally administered vaccines in that it can elicit both mucosal and systemic immune responses, generally with reduced secondary effects 32 . Additionally, mucosal vaccines can be administered without needles and syringes, eliminating the need for trained personnel 33 .
There is growing emphasis on the use of peptide vaccines due to their specificity, thereby reducing unnecessary antigenic load and potentially allergenic and/or reactogenic responses 4 . However, the foremost challenge is that peptides are often poorly immunogenic on their own and undergo enzymatic degradation more quickly than folded proteins 34 . These features necessitate chemical coupling to a stabilising carrier, and/or administration with potent immunostimulatory adjuvants 35 , posing greater costs and potential safety concerns. To overcome these problems, we have developed a novel peptide carrier platform for the presentation of peptides as an integral part of the GAS serotype M1 pilus on the surface of L. lactis. L. lactis is a non-pathogenic bacterium which has a 'generally recognised as safe' (GRAS) status 36 and has been thoroughly investigated as a delivery vehicle and adjuvant for mucosal vaccines 18, 22, 37, 38 . However, L. lactis produces a cell envelope structural component known as a polysaccharide pellicle, similar to a bacterial capsule, which might restrict accessibility of the heterologous protein 39 . It has previously been proposed that foreign proteins expressed on the tip of a pilus might overcome this problem by exposing the protein at a distance from the cell envelope 27 . The pilus structure of GAS has been shown to be highly immunogenic, and L. lactis possesses natural adjuvancy that induces IL-2 and IFN-γ cytokines 40 . The combination of these two elements provides the basis of promising efficacy for the PilVax platform as a vaccine strategy.
The GAS serotype M1 pilus consists of 3 structural proteins that are covalently connected by a pilus assembly sortase on the cell surface to form a long protruding peritrichous structure. The length of the pilus is determined by the number of backbone pilins (Spy0128) incorporated into the pilus fibre, which is estimated to consist of around 50-100 Spy0128 monomers 10, 15, 17 . Our strategy was to increase peptide stability and immunogenicity by inserting the model peptide Ova 324-339 into the compact (trypsin-resistant) and highly immunogenic backbone pilin, resulting in multimerisation of the peptide when the pilus structure is assembled ( Supplementary Figure  1) . Of the 8 potential integration sites within Spy0128 we analysed, 3 loop regions were found to be suitable for peptide expression. These include the βE-βF loop region in the N-terminal domain and the β3-β4 loop and β9-β10 loop regions in the C-terminal domain. Insertion of the model peptide Ova 324-339 into the βB-βC, β2-β3 loop regions or the βG-β1 interdomain regions resulted in expression of monomeric Spy0128 in the protoplast fraction indicating a lack of pilus assembly. Notably, the Spy0128 proteins were slightly larger than the rSpy0128, which lacks the N-terminal secretion sequence and the C-terminal sortase C assembly domain. This suggests that lack of proper protein maturation is responsible for the failed pilus assembly. In contrast, insertion of the Ova peptide into the βD-βE loop or at the free N-terminal region between Asn28 and Gly29 did not result in detectable Spy0128 in any of the cell fractions or the cell culture supernatant. This suggests that the proteins either failed to express or were rapidly degraded after expression. The exact reason for the failed expression of pili was not further analysed as this is irrelevant to this study. In the successful constructs, pilus expression was generally lower than in L. lactis expressing unmodified PilM1 without peptide. The reduced pilus expression level could be explained by shorter pili being assembled, or lower amounts of pili being produced on the surface. As only the overall amount of Ova 324-339 -carrying Spy0128 pilins is important for our study, not the length of the pili, we have not investigated this any further.
One of the successful constructs, L. lactis expressing PilM1 with Ova 324-339 at the βE-βF loop region (L. lactis PilM1-Ova) was used to intranasally immunise groups of mice and to test for Ova-specific antibody responses. Our study shows that L. lactis PilM1-Ova induces detectable Ova-specific IgA responses at mucosal sites (measured in saliva and BAL fluid) and in serum after intranasal vaccination. Antibody responses were measurable against ovalbumin by ELISA, indicating that the antibodies recognised the Ova 324-339 peptide as part of the complete protein. This suggests that PilVax might be a suitable peptide delivery platform to develop mucosal vaccines against respiratory pathogens. In addition, we found detectable Ova-specific IgG responses in serum samples of immunised mice. As systemic antibodies can reduce bacterial spreading from mucosal sites and prevent systemic disease 41 , this is an important finding demonstrating the suitability of developing the PilVax platform into effective vaccines. Furthermore, serum-derived IgG can also contribute significantly to immune defence in the lower respiratory tract and in the genitourinary mucosa 42 . Notably, Ova-specific IgG or IgA were not detected in serum or mucosal sites when synthetic Ova 324-339 was mixed with L. lactis PilM1. This indicates that the adjuvant property of L. lactis alone is not sufficient to induce Ova-specific immunity and suggests that the physical integration of the peptide into the pilus structure is important, probably due to peptide stabilisation and prevention of enzymatic degradation. The Ova-specific IgA response in BAL fluid was similar between L. lactis PilM1-Ova and Ova + CT-B immunised mice, even though the amount of synthetic Ova peptide was approximately 36,000-times higher in the Ova + CT-B group. This might again be due to the increased stability of the peptide when incorporated into the rigid pilus structure. Interestingly, no significant Ova-specific IgA titers were found in the serum after immunisation with Ova + CT-B. However, the reason for this is unclear.
Further investigation into the type of immune response generated by L. lactis PilM1-Ova showed a mixed IgG1/IgG2a systemic response. This was in contrast to the control immunisation with synthetic Ova 324-339 mixed with CT-B adjuvant, which generated a predominant IgG1 response. In mice, IgG1 is associated with a Th2-like response, while a Th1 response promotes the induction of IgG2a antibodies 43 . Yanase et al. recently reported that ovalbumin conjugated to nanoparticles (Ova-NPs) also stimulated a mixed IgG1/IgG2a Ova-specific response, and only low levels of unwanted and potentially toxic IgE antibodies in mice. In contrast, immunisation with Ova in alum stimulated Ova-specific IgG1 and IgE, but only low levels of IgG2a/IgG2b antibodies 44 . Notably, IgA was not detected in either of these schedules, likely due to the subcutaneous route of immunisation used in this study 44 .
We have further shown that it is possible to insert more than one peptide into the same integration site, expanding the versatility of the PilVax platform. Introducing unique restriction enzyme recognition sites into each of the 3 accommodating loop regions within the same construct could also further increase the number of different peptides that could be presented. Finally, we have shown that peptide epitopes can be incorporated into structurally similar, but antigenically different pilus structures, However, PilM18 expression was much lower than observed with PilM1 and therefore the suitability of this pilus type for peptide-presentation requires further evaluation.
One drawback of the PilVax platform is that peptide insertion, at least for the model Ova 324-339 peptide tested in this study, resulted in notable reduction in pilus expression level on the L. lactis surface. However, we have shown that significant Ova-specific IgA and IgG levels could be generated in mice immunised with the construct that had the lowest pilus expression (L. lactis PilM1-Ova βE-βF). Based on the assumption that higher pilus/peptide expression would lead to improved immune responses it would be advisable that for any future application with a vaccine peptide, all integration sites should be investigated in order to identify the construct that shows the highest pilus expression levels.
Although live L. lactis vectors have been investigated as vaccines against a variety of different antigens from various pathogens [18] [19] [20] [21] [22] 37, 38, 45, 46 , the lack of a biological containment strategy has hindered progress into clinical trials. One solution is the use of an auxotroph mutant to prevent selection by a plasmid-encoded antibiotic resistance gene, e.g. the L. lactis NZ9130 strain, which carries an alanine racemase gene deletion preventing growth in the absence of alanine 47, 48 . More recently, a non-GMO alternative to live L. lactis has been introduced which is based on hot acid-treated nucleotide-free L. lactis known as bacterium-like particles (BLP) 49, 50 .
In conclusion, we have developed a novel peptide delivery platform that might be useful for mucosal vaccinations against a variety of pathogens that colonise mucosal sites, such as Streptococcus pneumoniae, Neisseria gonorrhoeae, Chlamydia trachomatis and Staphylococcus aureus. As proof of concept, we have shown that insertion of the model peptide Ova 324-339 into the monomeric pilus backbone protein Spy0128 increases immunogenicity most likely due to peptide stabilisation and multimerisation. Other benefits of PilVax include low production costs, as no chemical coupling is required and the modified bacteria can easily be shipped in lyophilised form. Furthermore, no potentially toxic adjuvants are required and the vaccine can be delivered needle-free to a mucosal site. These advantages in safety, low production cost and ease of administration are highly desired in developing countries, where efficacious vaccines are most needed.
Methods
Bacterial strains and culture conditions. S. pyogenes strains SF370 (serotype M1) and MGAS8232 (serotype M18) were grown stationary in Brain Heart Infusion (BHI) broth (BD) at 37 °C, L. lactis MG1363 was grown stationary in M17 media (BD) supplemented with 0.5% glucose at 28 °C, and E. coli DH5α was grown aerobically Genetic manipulations. The complete pilus operon was amplified from S. pyogenes SF370 or MGAS8232 genomic DNA by PCR using iProof DNA polymerase (Roche) and primers shown in Table 2 . The purified PCR products were digested with BamHI (PilM1) or BamHI/PstI (PilM18) and cloned into plasmid pLZ12km2_ P23R 51, 52 to generate pLZ12km2_P23R:PilM1 and pLZ12km2_P23R:PilM18.
The unique XhoI in the vector's multiple cloning site was first deleted, then re-introduced by full circle PCR with specific primers shown in Table 2 followed byXhoI digestion and religation. This allowed the insertion of peptide-encoding DNA sequences with flanking XhoI or SalI restriction sites. The DNA encoding Ova 324-339 and J14 31 peptides were generated by PCR with overlapping primers (see Table 2 ), digested with XhoI and SalI and cloned into selected XhoI sites previously introduced into the pilus backbone genes as described above.
DNA sequences were confirmed by Sanger sequencing using the DNA sequencing service at the School of Biological Sciences (The University of Auckland, New Zealand). L. lactis strain MG1363 was transformed by electroporation with the resulting plasmids at 2100 V, 25 μF, 200 Ω in a 2 mm cuvette using a Gene Pulser Xcell TM (Bio-Rad).
Bioinformatic analysis. The structural model of the FCT-3 backbone pilin was generated using the Swiss PDB modelling server at the Swiss Institute of Bioinformatics 53 with Spy0128 (3B2M) as a template. The structural images were created with the PDB Swiss Viewer version 4.1.0. 54 .
Cell wall extracts and Western blots. An overnight L. lactis culture was spun down at 4,500 rpm for 15 min at 4 °C. The bacterial cell pellet was washed once with PBS, then resuspended at 0.1 g/ml in cold protoplast buffer (40% sucrose, 10 mM MgCl 2 , 0.1 M KPO 4 , 2 mg/ml lysozyme, 400 U mutanolysin, Roche EDTA-free protease inhibitor) and incubated for 3 h at 37 °C with constant rotation. Cellular debris was removed by centrifugation at 13,000 × g for 15 min at 4 °C, and the supernatant containing cell surface proteins were run on a NuPAGE TM Novex TM 4-12% gradient gel (Invitrogen). Separated proteins were transferred onto a nitrocellulose (N+) membrane (Biotrace NT, Pall Life Science, USA) in NuPAGE ™ Transfer Buffer (Invitrogen) using a Hoefer TE77 Semi-phor semi-dry transfer unit. The membrane was blocked with 5% (w/v) non-fat milk in TBS, 0.5% (v/v) tween 20 (TBS-T), then probed with polyclonal rabbit antibodies against M1_Spy0128, M18_Spy0128 26 or serum from Ova + CT-B immunised mice. After intensive washing in TBS-T, the membrane was then probed with goat anti-rabbit or goat anti-mouse HRP-conjugated antibody. The membrane was washed again before being developed using Amersham ECL Prime Western blotting detection reagent (GE Healthcare). Chemiluminescence signals were captured and digitised into image using a ChemiDoc ™ Imaging System (Bio-Rad).
Flow cytometry. L. lactis strains were grown overnight in GM17 medium, harvested by centrifugation (5000 × g, 5 min), and resuspended in 1 ml blocking buffer (PBS/3% FBS/5 mM EDTA) at an OD 600 of 0.4. Cells were dispersed in a water bath sonicator for 2 min, then incubated on ice for 30 min. Blocking buffer was removed by centrifugation, and bacteria were washed once with FACS buffer (PBS/1% FBS/5 mM EDTA) and incubated with anti-Spy0128 antibody in FACS buffer on ice for 30 min. Bacteria were washed once, then incubated with anti-rabbit IgG FITC (Abacus ALS Ltd.) on ice for 30 min. Flow cytometry analysis was performed on a LSRII Flow Cytometer and analysed using FlowJo software.
Immunisations. Frozen aliquots of L. lactis were prepared as previously described 26 and enumerated by plating. On immunisation days, an aliquot was thawed at RT, washed and resuspended in PBS. Five to six week old Balb/c mice (n = 5) were immunised intranasally, under isoflurane anaesthesia, with 1 × 10 8 CFU live recombinant L. lactis with or without 1.4 ng Ova peptide, 1.4 ng Ova peptide alone, or 50 μg Ova peptide + 4 μg CT-B, in a 10 μl volume. The bacterial suspensions were administered on 3 consecutive days (day 0, 1 and 2) as described previously 27 . An additional 3 boosters were given, 1-2 weeks apart, for a total of 12 doses (days 0, 1, 2, 14, 15, 16, 28, 29, 30, 35, 36, 37) . Pre-immune serum was collected on day 0 and immune serum was collected 1 week after final immunisation (day 44). Bronchoalveolar lavage (BAL) was performed with 1 ml PBS, and saliva samples collected by rinsing the oral cavity with 50 μl PBS on day 44.
ELISA.
MaxiSorp plates (Nunc) were coated with 1 μg/ml recombinant Spy0128 protein or commercial ovalbumin protein (Invivogen) in PBS overnight at 4 °C, prior to incubation with titrated serum, BAL fluid or saliva. Detection was performed using goat anti-mouse IgG/IgG1/IgG2a-HRP (Life Technology) or goat anti-mouse IgA-HRP (Invitrogen) and 3,3,5,5-tetramethylbenzidine (ThermoFisher). Absorbance was determined on an EnSpire multilabel plate reader (Perkin Elmer). Endpoint titres were determined as the minimum serum dilution above the control (absorbance of 1:200 dilution of pre-immune serum plus 3 times the standard deviation).
Animal Ethics. All animal experiments were performed in the Vernon Jansen Unit (University of Auckland, New Zealand) in accordance with relevant guidelines and regulations approved by the University of Auckland Animal Ethics Committee.
